PMID- 29977418
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1918-3003 (Print)
IS  - 1918-3011 (Electronic)
IS  - 1918-3003 (Linking)
VI  - 10
IP  - 8
DP  - 2018 Aug
TI  - SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in 
      Understanding the Current Outcome Trials and Possible Benefits of Combining 
      SGLT-2 Inhibitors With GLP-1 Agonists.
PG  - 615-625
LID - 10.14740/jocmr3467w [doi]
AB  - Landmark trials on diabetes control have shown variable results in terms of 
      cardiovascular benefits, with the majority showing a favorable effect of glycemic 
      control on microvascular and, more recently, macrovascular complications. 
      However, some trials pointed out a CV hazard with tight diabetes mellitus (DM) 
      control. Most of those trials were assessing the impact of glycemic control, more 
      than evaluating the effect of a certain medication. In the last decade, food and 
      drugs administration (FDA) has mandated that all new hypoglycemic agents run a CV 
      outcome trial (CVOT) for safety in order to grant and sustain approval. The most 
      stunning results came from relatively new agents in the field of diabetes 
      management, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and the 
      glucagon-like peptide-1 agonists (GLP-1 agonists), details of these CVOTs will be 
      addressed later in this document. SGLT2i effect on the cardiovascular system 
      remains an area of extensive research. We aimed in this review to summarize what 
      is the current evidence of cardiovascular protection upon using SGLT2i. Moreover, 
      we wanted to raise a point that may be strongly adopted in the future, combining 
      SGLT2i plus GLP-1 agonists, having a cardiovascular privilege in both molecules.
FAU - Abdelgadir, Elamin
AU  - Abdelgadir E
AD  - Dubai Hospital, Dubai, UAE.
FAU - Rashid, Fauzia
AU  - Rashid F
AD  - Dubai Hospital, Dubai, UAE.
FAU - Bashier, Alaaeldin
AU  - Bashier A
AD  - Dubai Hospital, Dubai, UAE.
FAU - Ali, Razan
AU  - Ali R
AD  - Dubai Hospital, Dubai, UAE.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180627
PL  - Canada
TA  - J Clin Med Res
JT  - Journal of clinical medicine research
JID - 101538301
PMC - PMC6031247
OTO - NOTNLM
OT  - Cardiovascular protection
OT  - Diabetes
OT  - GLP-1 agonist
OT  - SGLT2
EDAT- 2018/07/07 06:00
MHDA- 2018/07/07 06:01
PMCR- 2018/06/27
CRDT- 2018/07/07 06:00
PHST- 2018/05/09 00:00 [received]
PHST- 2018/06/04 00:00 [accepted]
PHST- 2018/07/07 06:00 [entrez]
PHST- 2018/07/07 06:00 [pubmed]
PHST- 2018/07/07 06:01 [medline]
PHST- 2018/06/27 00:00 [pmc-release]
AID - 10.14740/jocmr3467w [doi]
PST - ppublish
SO  - J Clin Med Res. 2018 Aug;10(8):615-625. doi: 10.14740/jocmr3467w. Epub 2018 Jun 
      27.